케이바이오
Financials
Valuation Metrics
케이바이오's Market Cap is ₩259B. At end of 2025 it was ₩312B. Ranked #2185 of 2,421 in KR market (top 90%), #1425 of 1,640 on KOSDAQ (top 87%), #94 of 114 in Consumer Durables & Apparel (top 82%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 25.86B KRW | KR#2,185/2,421 Sec#94/114 |
| Revenue | 74.08B KRW | KR#1,590/2,421 Sec#88/114 |
| Net Income | -41.72B KRW | KR—/2,421 Sec—/114 |
| Total Assets | 74.37B KRW | KR#1,979/2,421 Sec#100/114 |
| Net Assets | 63.19B KRW | KR#1,754/2,421 Sec#88/114 |
| Employees | 33 | KR#2,182/2,421 Sec#105/114 |
| Value | ||
| P/B | 0.41x | KR#590/2,421 Sec#55/114 |
| P/S | 0.35x | KR#677/2,421 Sec#55/114 |
| FCF Yield | 31.55% | KR#170/2,421 Sec#12/114 |
| Profitability | ||
| ROE | -66.03% | KR#2,313/2,421 Sec#110/114 |
| ROA | -56.10% | KR#2,373/2,421 Sec#114/114 |
| Op. Margin | 1.19% | KR#1,485/2,421 Sec#68/114 |
| Revenue Growth | -10.52% | KR#1,936/2,421 Sec#90/114 |
| Financial Health | ||
| Debt Ratio | 17.69% | KR#315/2,421 Sec#19/114 |
| FCF | 8.16B KRW | KR#770/2,421 Sec#39/114 |
| Cash | 2.46B KRW | KR#2,202/2,421 Sec#102/114 |
| Current Ratio | 6.08x | KR#213/2,421 Sec#10/114 |
| Performance | ||
| 1Y Return | -29.65% | KR—/2,421 Sec—/114 |
| 1M Return | 21.39% | KR—/2,421 Sec—/114 |
| From 52W High | -63.67% | KR#1,993/2,421 Sec#95/114 |
| 1Y MDD | -70.81% | KR#2,022/2,421 Sec#96/114 |
| Trading | ||
| Volume | 143,563 shares | KR—/2,421 Sec—/114 |
| Trading Value | 138.8M KRW | KR—/2,421 Sec—/114 |
| Foreign Own. | 4.02% | KR#1,044/2,421 Sec#40/114 |
| Per Share | ||
| EPS | -1,612 KRW | KR—/2,421 Sec—/114 |
| BPS | 2,441 KRW | KR#1,968/2,421 Sec#97/114 |
Company Info
K-Bio, established in 1997, expanded its business by acquiring CureBio's distribution division, adding a bio-distribution segment. The company operates two main businesses: distributing life science equipment and reagents, and developing video security equipment and ICT solutions. Leveraging agency contracts with global firms, K-Bio supplies products to universities and hospitals across Seoul and Gyeonggi. The company is actively developing and launching new IoT-based ICT products, including integrated control solutions and GIS MAP systems, from its headquarters in Gangdong-gu, Seoul.